Navigation Links
Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplants
Date:2/18/2009

CINCINNATI Screening for mutations in a gene that helps the body metabolize a kidney transplant anti-rejection drug may predict which children are at higher risk for side effects, including compromised white blood cell count or organ rejection, according to new research.

Published online Feb. 18 by the Nature journal Clinical Pharmacology and Therapeutics, the study suggests this genetic approach could also help physicians tailor personalized anti-rejection drug doses to prevent adverse reactions, said senior investigators Alexander A. Vinks, Pharm.D., Ph.D., and Jens Goebel M.D., of Cincinnati Children's Hospital Medical Center.

"There are better ways than just giving standard doses of these drugs, and in due course these types of technologies will be available worldwide to help patients," said Dr. Vinks, director of the Division of Clinical Pharmacology and the Pediatric Pharmacology Research Unit at Cincinnati Children's. "This pilot study shows personalized and prospective MMF dosing and monitoring may be feasible to reduce the high incidence of drug toxicity in children without compromising the drug's protective effects against kidney graft rejection."

MMF, or Mycophenolate Mofetil, is an immunosuppressive agent commonly used to prevent rejection in organ transplants, particularly in kidney transplants. After taken orally, the drug is quickly processed by the body into active form. During this time, patients with a specific point mutation in the gene that helps break down the drug, UGT, metabolize the drug slower. This point mutation, called UGT1A9-331, causes overexposure and adverse side effects in the affected children, the study concluded. UGT encodes the drug's main metabolizing enzyme in the body, uridine diphosphate-glucuronosyl transferase.

Adverse side effects most commonly linked to MMF have included gastrointestinal complications (such as diarrhea) or leukopenia a drop in white blood cell count that can put patients at higher risk for infections. In some instances, patients have to be taken off the drug or have their dosage reduced to the point where they risk rejection of the new organ.

The current study analyzed 38 children who had received kidney transplants. Sixteen of the children experienced adverse side effects from MMF therapy. In the adverse reaction group, nine children with the specific UGT point mutation developed leukopenia. The researchers found no strong association between UGT gene variants and diarrhea the most common side effect linked to MMF suggesting gastrointestinal reactions to the drug may be caused by other factors.

Some previous studies have linked UGT gene mutations and MMF-related side effects in kidney transplant recipients, while others have suggested a greater risk for adverse events in children. A review of earlier research combined with their current data led researchers in this study to conclude that pediatric kidney transplant recipients on MMF therapy have a significantly higher likelihood of drug-related complications than adult patients. One previous study compared 22 pediatric and 37 adult transplant recipients, all who started with the standard recommended doses of MMF. Among the children, 54.5 percent experienced adverse side effects compared to 21.6 percent of the adults.

Besides the UGT1A9-331 point mutation, other studies have also linked a second variation, called UGT2B7-900, to possible MMF overexposure and development of leukopenia, said Tsuyoshi Fukuda, Ph.D., co-author on the current study and a colleague in Dr. Vinks' division at Cincinnati Children's. The research team recently completed pharmacokinetic and biomarker studies which analyze how the body metabolizes a drug to solidify the connection between different variants of UGT and MMF overexposure in pediatric kidney transplant patients.

Researchers want to use data from these pharmacokinetic studies as a basis for showing whether increased MMF exposure in adults can also be linked to specific variations in the UGT gene, according to Dr. Fukuda.

The pilot study is part of the growing field of genetic-based pharmacology, or pharmacogenetics. Combining biology and information technology, researchers are developing computer-based algorithms that allow taking a few drops of blood and analyzing how quickly a person's body will break down and absorb a drug based on their genetic makeup. The goal is to reduce drug-related side affects by optimizing drug doses for individual patients.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related biology news :

1. Presence of gene mutation helps guide thyroid cancer treatment
2. Mutation of the COX2 gene can double or treble a womans risk of ovarian cancer
3. New study reveals for first time how BRCA1 mutations cause breast cancer
4. Men unaware of their cancer risk when female relatives test positive for BRCA mutation
5. Varying prevalence among ethnic groups of gene mutation that increases risk of breast cancer
6. Mutation may cause inherited neuropathy
7. Should children be permitted to get genetic testing for BRCA 1/2 mutations?
8. CSHL scientists part of team that discovers role of rare gene mutations in schizophrenia
9. Rare genetic mutations protect against hypertension
10. Inherited cancer mutation is widespread in America
11. Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
Breaking Biology News(10 mins):
(Date:8/14/2017)... ... August 14, 2017 , ... Opal Kelly, ... USB or PCI Express, announced the release of SYZYGY™, a new open standard ... the need for a compact, low cost, low pin-count, high-performance connectivity solution between ...
(Date:8/11/2017)... Md. , Aug. 11, 2017 /PRNewswire/ ... a New York Times article regarding the ... billion, according to Kalorama Information.  The article, ... App for That"  used information from ... Patient Monitoring & Telemedicine Market  (Sleep, Diabetes, ...
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS Liquid ... the key structural element skin needs to maintain its youthful appearance and Algenist is ... First to market with proprietary collagen water active , Active ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... agriculture industry reach its ideal customers with the right message. Their effective, cutting-edge ... a Midwest company, we realize how crucial the agriculture industry is,” said David ...
Breaking Biology Technology: